1st December 2020
LC Therapeutics announces significant investment from Medical Incubator Japan
ILC Therapeutics has secured substantial funding from its first international investor, Medical Incubator Japan (MIJ). The venture capital company targets early-stage life sciences companies,
whether drug discovery, digital health or medical devices, both in Japan and abroad.
ILC Therapeutics is the organisation’s first European investment, and the company was particularly attracted to the innovation and world-class science burgeoning within the UK life sciences space
at present. Japan is the third largest healthcare market in the world, and this partnership will enable ILC Therapeutics to access and establish itself within this market going forward.
This investment comes at a time when ILC Therapeutics is receiving growing recognition as a key player in modulating the Innate Immune System, and demonstrates the increasing interest within this field worldwide.
To read the full press release, please click here.